Publications
Pseudoprogression Associated with Clinical Deterioration and Worsening Quality of Life in Malignant Pleural Mesothelioma
Abstract
Malignant pleural mesothelioma (MPM) is an aggressive asbestos-related malignancy with limited treatment options. Immune checkpoint inhibition has demonstrated promising activity in MPM with the use of single-agent pembrolizumab in a mostly chemotherapy-resistant population.1 Here we report significant responses to pembrolizumab after pseudoprogression in two patients with MPM and corresponding patient-reported outcomes (PROs) related to quality of life.
| Type | Journal |
|---|---|
| ISBN | 1556-1380 (Electronic) 1556-0864 (Linking) |
| Authors | Barnet, M. B.; Zielinski, R. R.; Warby, A.; Lewis, C. R.; Kao, S. |
| Responsible Garvan Author | Megan Barnet |
| Publisher Name | Journal of Thoracic Oncology |
| Published Date | 2018-01-01 |
| Published Volume | 12 |
| Published Issue | 12 |
| Published Pages | e1-e2 |
| Status | Published in-print |
| DOI | 10.1016/j.jtho.2017.09.001 |
| URL link to publisher's version | https://www.ncbi.nlm.nih.gov/pubmed/28919393 |